Dietary quality in early-onset gastrointestinal malignancies: NHANES 2005-2018. Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best ...

Circulating tumor cells as a biomarker for monitoring: Disease progression, treatment response, and minimal residual disease. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...